Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus conversion versus ciclosporin for bone density after renal transplantation
2006-006652-35Phase 3Terminated
- Sponsor
- Queen Mary University of London
- Start
- Jul 2007
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of sirolimus, cyclosporine, mycophenolate mofetil, daclizumab and corticosteroids in Kidney allograft status (RTx) (2 arms), sponsored by Queen Mary University of London. Primary endpoints: Change in bone density and Severity of bone loss. Started Jul 2007; status: terminated.
02
Drugs
sirolimuscyclosporinemycophenolate mofetildaclizumabcorticosteroids
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2006-006652-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006652-35.